Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/18715Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Korantzopoulos, P. | en |
| dc.contributor.author | Kokkoris, S. | en |
| dc.contributor.author | Kountouris, E. | en |
| dc.contributor.author | Protopsaltis, I. | en |
| dc.contributor.author | Siogas, K. | en |
| dc.contributor.author | Melidonis, A. | en |
| dc.date.accessioned | 2015-11-24T18:54:40Z | - |
| dc.date.available | 2015-11-24T18:54:40Z | - |
| dc.identifier.issn | 1874-1754 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/18715 | - |
| dc.rights | Default Licence | - |
| dc.subject | Atrial Fibrillation/*prevention & control | en |
| dc.subject | Diabetes Mellitus, Type 2/drug therapy | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Hypoglycemic Agents/*therapeutic use | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Thiazolidinediones/*therapeutic use | en |
| dc.title | Regression of paroxysmal atrial fibrillation associated with thiazolidinedione therapy | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1016/j.ijcard.2006.12.063 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/17400309 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S0167527307003774/1-s2.0-S0167527307003774-main.pdf?_tid=f01c96ed57fbc177d352eb4e60e948e9&acdnat=1333963299_953f07e70a408955e4ae6092bcba5999 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2008 | - |
| heal.abstract | Thiazolidinediones (TZDs) represent insulin-sensitizing agents that have several pleiotropic properties, possibly related to their favorable effects on cardiovascular remodeling. We briefly describe 2 diabetic patients who experienced a remarkable improvement in their paroxysmal atrial fibrillation (AF) after treatment with rosiglitazone. Current evidence suggests that atrial remodeling represents a prominent mechanism of AF development and perpetuation while inflammation and oxidative stress are possibly implicated in this process. It could therefore be speculated that the pleiotropic effects of TZDs favorably affect atrial remodeling reducing the arrhythmia burden. Further studies are needed in order to elucidate the merit of this pharmacological approach in AF. | en |
| heal.journalName | Int J Cardiol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Korantzopoulos-2008-Regression of paroxy.pdf | 94.19 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
